NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

Thanks for the summary ATLnsider.

You said:

(3) Two other slides showed that when a DC Vaccine is combined with a PD-1 inhibitor, for ndGBM it is better to treat with the PD-1 inhibitor on a neoadjuvant basis, and for rGBM, it is better to treat with the PD-1 inhibitor on an adjuvant basis.

I’m not aware of a clinical study in newly diagnosed GBM with the PD-1 inhibitor on a neoadjuvant basis + DC Vaccine.
Can you give more details about the study you're talking about?

In the new SPORE clinical trial (not started yet) Pembrolizumab will be given after surgery (on an adjuvant basis)

Clinical Trial: DC vaccine/Poly-ICLC +/- PD-1 blockade and CSF-1Ri in newly diagnosed GBM patients.

Initial Diagnosis
Initial Surgery
6 weeks XRT/TMZ
RANDOMIZE
3 different arms:
Group A : ATL-DC + Pembrolizumab + PLX 3397 (N=10) until progression.
Group B : ATL-DC + PLX 3397 (N=10)
Group C : ATL-DC + Pembrolizumab (N=10)

Pembrolizumab = 400mg (6 weeks)
PLX3397 = 100mg daily oral
ATL-DC = 2 wks x 3

All patients will be allowed to get PLX 3397 + Pembrolizumab 6-8 weeks after randomization.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168683019
You said:

(4) For patients with rGBM, and treated with a DC Vaccine plus a PD-1 on an adjuvant basis, the mOS has not been reached yet, and it is approaching 800 days (26.67 months).

It’s a small group of patients. A few patients died and the majority of the patients in the DC Vaccine + PD-1(adjuvant) group are censored between 4 and 24 months.